These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18541632)

  • 1. The role of clinical imaging in oncological drug development.
    Murphy PS; McCarthy TJ; Dzik-Jurasz AS
    Br J Radiol; 2008 Sep; 81(969):685-92. PubMed ID: 18541632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical imaging in pharmaceutical clinical trials: what radiologists should know.
    Wang YX
    Clin Radiol; 2005 Oct; 60(10):1051-7. PubMed ID: 16179164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualification of imaging biomarkers for oncology drug development.
    Waterton JC; Pylkkanen L
    Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of molecular imaging in drug discovery and development.
    Hargreaves RJ
    Clin Pharmacol Ther; 2008 Feb; 83(2):349-53. PubMed ID: 18167503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
    Sistare FD; DeGeorge JJ
    Biomark Med; 2011 Aug; 5(4):497-514. PubMed ID: 21861671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging in drug development.
    Herbst RS
    Clin Adv Hematol Oncol; 2004 May; 2(5):268-9. PubMed ID: 16163191
    [No Abstract]   [Full Text] [Related]  

  • 12. Validation of analytic methods for biomarkers used in drug development.
    Chau CH; Rixe O; McLeod H; Figg WD
    Clin Cancer Res; 2008 Oct; 14(19):5967-76. PubMed ID: 18829475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using imaging biomarkers to accelerate drug development and clinical trials.
    Pien HH; Fischman AJ; Thrall JH; Sorensen AG
    Drug Discov Today; 2005 Feb; 10(4):259-66. PubMed ID: 15708744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular imaging with SPECT as a tool for drug development.
    Gomes CM; Abrunhosa AJ; Ramos P; Pauwels EK
    Adv Drug Deliv Rev; 2011 Jun; 63(7):547-54. PubMed ID: 20933557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials in drug development: a minimalistic approach.
    Verweij J
    Curr Opin Oncol; 2012 May; 24(3):332-7. PubMed ID: 22343389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategic approach to fit-for-purpose biomarkers in drug development.
    Wagner JA
    Annu Rev Pharmacol Toxicol; 2008; 48():631-51. PubMed ID: 17937595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The progress and promise of molecular imaging probes in oncologic drug development.
    Kelloff GJ; Krohn KA; Larson SM; Weissleder R; Mankoff DA; Hoffman JM; Link JM; Guyton KZ; Eckelman WC; Scher HI; O'Shaughnessy J; Cheson BD; Sigman CC; Tatum JL; Mills GQ; Sullivan DC; Woodcock J
    Clin Cancer Res; 2005 Nov; 11(22):7967-85. PubMed ID: 16299226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging in clinical trials.
    Murphy P; Koh DM
    Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S74-82. PubMed ID: 20880784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography imaging of small animals in anticancer drug development.
    Aboagye EO
    Mol Imaging Biol; 2005; 7(1):53-8. PubMed ID: 15912276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.